T-DXd Benefits Persist for HER2-Low Breast Cancer T-DXd Benefits Persist for HER2-Low Breast Cancer

Trastuzumab deruxtecan (T-DXd) provided sustained clinically meaningful improvement versus physician ’s choice of treatment (TPC) for patients with advanced breast cancer and low HER2 expression.MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news